Ruth M. O’Regan, MD, and Debu Tripathy, MD, on HR+, HER2– Breast Cancer: Results From the MONALEESA-7 Trial

Posted: Thursday, December 7, 2017

Ruth M. O’Regan, MD, of the University of Wisconsin Carbone Cancer Center, and Debu Tripathy, MD, of The University of Texas MD Anderson Cancer Center, discuss phase III study findings on first-line ribociclib vs placebo with goserelin and tamoxifen or a nonsteroidal aromatase inhibitor in premenopausal women with hormone receptor–positive, HER2-negative advanced breast cancer.